CITIC Capital Partners, the private equity arm of CITIC Capital, has invested CNY1.5 billion (approximately US$231 million) to increase its stake in China-based Harbin Pharmaceutical Group from 45 percent to 60.86 percent. CITIC originally invested in Harbin, which produces antibiotics, modern Chinese medicines and animal vaccines, in 2005 and 2017.